We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

In a report released today, Asthika Goonewardene from Truist Financial reiterated a Buy rating on Merus (MRUS – Research Report). The company’s ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...

Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...

FDA approves Merus' Bizengri for advanced pancreatic adenocarcinoma ... of roughly $16.5 million. Price Action: MRUS stock is down 3.70% at $43.80 at the last check on Thursday.